Alessandra Bisagni

8PUBLICATIONS
52CO-AUTHORS
Medical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsMedicinal and biomolecular chemistry not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 13, 2025
Metastatic Carcinomas at the Episiotomy Site: A Systematic Literature Review.

Andrea Palicelli, Gabriele Tonni, Federica Torricelli

|Oct 19, 2023
Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Benedetta Donati, Francesca Reggiani, Federica Torricelli

|Jul 07, 2023
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer.

Federica Miglietta, Moira Ragazzi, Bethania Fernandes

|Nov 27, 2021
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1.

Andrea Palicelli, Stefania Croci, Alessandra Bisagni

|Apr 25, 2018
Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.

Alessandra Bisagni, Maria Pagano, Sally Maramotti

|Jul 15, 2017
Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan.

M Zanelli, A Negro, R Santi

Pageof 2

Frequent Collaborators

3 joint publications

Giacomo Santandrea

2 joint publications

Giancarlo Bisagni

2 joint publications

Andrea Palicelli

2 joint publications

Eleonora Zanetti